| Dr Timothy M Capstack, MD | |
|
2001 Medical Pkwy, Annapolis, MD 21401-3280 | |
| (443) 481-1000 | |
| (443) 949-0825 |
| Full Name | Dr Timothy M Capstack |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 28 Years |
| Location | 2001 Medical Pkwy, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073534319 | NPI | - | NPPES |
| 015649300 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | D66753 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mdics At Anne Arundel Llc | 1456515519 | 30 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
| Entity Name | Luminis Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073580205 PECOS PAC ID: 2860447315 Enrollment ID: O20050317000146 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
| Entity Name | Upper Chesapeake Medical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497801419 PECOS PAC ID: 3173556974 Enrollment ID: O20050913000525 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
| Entity Name | Mdics At Civista Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225323496 PECOS PAC ID: 8325200793 Enrollment ID: O20120501000281 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
| Entity Name | Mdics At Anne Arundel Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427343664 PECOS PAC ID: 1456515519 Enrollment ID: O20120621000282 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
| Entity Name | Mdics At Meritus Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306258645 PECOS PAC ID: 3173742590 Enrollment ID: O20140917002568 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
| Entity Name | Adfinitas Health At Upper Chesapeake Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164134037 PECOS PAC ID: 6305202540 Enrollment ID: O20230515001078 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
| Entity Name | Adfinitas Health At Upper Chesapeake Harford Memorial Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457051724 PECOS PAC ID: 5799141388 Enrollment ID: O20230524002364 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
| Entity Name | Adfinitas Health At Upper Chesapeake Aberdeen Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346941010 PECOS PAC ID: 8022475581 Enrollment ID: O20230530000304 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Timothy M Capstack, MD 7250 Parkway Dr Ste 500, Hanover, MD 21076-1343 Ph: (443) 949-0814 | Dr Timothy M Capstack, MD 2001 Medical Pkwy, Annapolis, MD 21401-3280 Ph: (443) 481-1000 |
News Archive
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
MRO Corp., a leading provider of disclosure management applications and services for healthcare organizations, today announced that it has acquired the assets of Keystone Management Solutions, a provider of release of information services based in Malvern, Pennsylvania. This acquisition will enable MRO to continue building its market presence across Pennsylvania, Massachusetts and Louisiana, where Keystone Management Solutions currently serves hospitals and health systems.
A new research paper published in the American Journal of Clinical Nutrition last week showed that a low Omega-3 Index is just as powerful in predicting early death as smoking. This landmark finding is rooted in data pulled and analyzed from the Framingham study, one of the longest running studies in the world.
› Verified 4 days ago
Sonia Mannan Solomon, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2001 Medical Parkway, Acute Care Pavilion, Annapolis, MD 21401 Phone: 443-481-1000 Fax: 443-481-1687 | |
Melsjan Shkullaku, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 128 Lubrano Dr Ste 301, Annapolis, MD 21401 Phone: 443-607-2299 Fax: 443-782-3488 | |
Dr. Dmitriy V. Pinelis, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 443-481-1000 | |
Dr. Michael Atkinson, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 443-481-1000 | |
Spencer Frances Martin, CRNP Hospitalist Medicare: Medicare Enrolled Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 410-507-8279 | |
Dr. Eileen B Macdonald, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 443-481-1000 |